IMARC Group, a leading market research company, has recently releases a report titled “Oncology Based In-vivo CRO Market Report, Industry Size, Share and Forecast 2023-2028.” The study provides a detailed analysis of the industry, including the global oncology based in-vivo CRO market share, size, trends, and growth forecasts. The report also includes competitor and regional analysis and highlights the latest advancements in the market.
Report Highlights
How Big is the Oncology Based In-vivo CRO Market?
The global oncology based in-vivo CRO market size reached US$ 1.1 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 1.8 Billion by 2028, exhibiting a growth rate (CAGR) of 7.65% during 2023-2028.
What is Oncology Based In-vivo CRO?
Oncology is a specialized medical discipline dedicated to understanding, diagnosing, and treating cancer. It employs a range of diagnostic tools including biopsy, X-rays, CT scans, MRI, PET scans, endoscopy, and ultrasound to identify and analyze the disease. Oncology provides diverse therapeutic solutions, including hormonal therapy, immunotherapy, radiotherapy, and oral treatments, to help patients manage cancer and mitigate its side effects. In recent times, there has been a significant surge in global interest in oncology-based in-vivo Contract Research Organizations (CROs) due to the strides made by these organizations in developing innovative cancer treatments.
Request Free Sample Copy of This Report:
https://www.imarcgroup.com/oncology-based-in-vivo-cro-market/requestsample
What are the growth prospects and trends in the oncology based in-vivo CRO industry?
The global market for oncology-based in-vivo Contract Research Organizations (CROs) is primarily fueled by the increasing prevalence of cancer. Additionally, the growing use of genetic engineering techniques to modify organism characteristics and the heightened focus on studying oncogenes to regulate cell growth, differentiation, and proliferation are contributing positively to market expansion.
Another significant factor driving growth is the cost-effectiveness of CROs compared to in-house studies. Moreover, the rising adoption of telehealth and virtual clinical trials in the healthcare sector, aimed at ensuring the safety of cancer patients, is further propelling market growth.
Additionally, factors such as increased investments in research and development (R&D) activities, easy accessibility to medicines, and the rapid expansion of the healthcare industry are expected to create a favorable market outlook.
What is included in market segmentation?
The report has segmented the market into the following categories:
Breakup by Indication:
- Blood Cancer
- Solid Tumors
- Others
Breakup by Model:
- Syngeneic
- Xenograft
- Patient Derived Xenograft (PDX)
- Others
Breakup by Application:
- Hospitals
- Rehabilitation Centers
Market Breakup by Region:
- North America (United States, Canada)
- Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa
Who are the key players operating in the industry?
The report covers the major market players including:
- Champions Oncology Inc.
- Charles River Laboratories International Inc.
- Crown Bioscience Inc.
- Eurofins Scientific
- Evotec SE
- ICON Plc
- Labcorp Drug Development (Laboratory Corporation of America Holdings)
- Living Tumor Laboratory
- Taconic Biosciences Inc.
- The Jackson Laboratory
- WuXi AppTec
- Xentech
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC Group’s information products include major market, scientific, economic, and technological developments for business leaders in pharmaceutical, industrial, and high-technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology, and novel processing methods are at the top of the company’s expertise.
Contact US
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
USA: +1-631-791-1145 | Asia: +91-120-433-0800
Email: sales@imarcgroup.com
Follow us on Twitter: @imarcglobal
LinkedIn: https://www.linkedin.com/company/imarc-group/mycompany/
